Source: Annual Congress 2013 –Sarcoidosis



Rating:

Share or cite this content

Citations should be made in the following way:
A. D. M. Vorselaars, A. Verwoerd, C. H. M. Van Moorsel, R. G. M. Keijsers, G. T. Rijkers, J. C. Grutters (Nieuwegein, Middelburg, Utrecht, Netherlands). Relapse after discontinuation of infliximab in sarcoidosis patients can be predicted by PET-scan and sIL-2R. Eur Respir J 2013; 42: Suppl. 57, 3063

Member's Comments

No comment yet.

Related content which might interest you: Infliximab in patients with refractory sarcoidosis: Trough concentrations of infiximab Source: International Congress 2015 – Clinical problems in acute and chronic lung diseases Year: 2015 Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab Source: International Congress 2016 – Sarcoidosis Year: 2016 Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis Source: Eur Respir J 2014; 43: 602-609 Year: 2013 Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Sarcoidosis relapses in corticosteroid treated patients Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura Year: 2012 Are there any predictors of MTX response in progressive pulmonary sarcoidosis? Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice Year: 2015 Unusual multisystemic relapse of sarcoidosis after corticosteroids withdrawal Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Source: Eur Respir J 2008; 31: 1189-1196 Year: 2008 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Corticosteroid treatment in sarcoidosis Source: Eur Respir J 2006; 28: 627-636 Year: 2006 Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014 Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 ANCA associated vasculitis – Evaluation of diagnosis, treatment and outcome in a group of 68 patients Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis Source: Eur Respir J 2015; 46: 175-185 Year: 2015 Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Anti-inflammatory therapy for sarcoidosis patients Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013